$373 Million is the total value of MPM BioImpact LLC's 37 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $80,077,000 | -32.1% | 7,648,268 | 0.0% | 21.49% | -0.1% | |
| ITOS | Sell | iTeos Therapeutics, Inc. | $56,184,000 | -34.6% | 1,745,943 | -5.4% | 15.08% | -3.7% |
| MRUS | Sell | Merus N.V. | $24,311,000 | -17.6% | 919,482 | -0.8% | 6.52% | +21.4% |
| RPTX | Repare Therapeutics, Inc. | $23,351,000 | -32.5% | 1,639,849 | 0.0% | 6.27% | -0.6% | |
| HARP | Harpoon Therapeutics, Inc. | $15,888,000 | -34.2% | 3,196,707 | 0.0% | 4.26% | -3.1% | |
| NTLA | Sell | Intellia Therapeutics, Inc. | $11,584,000 | -39.0% | 159,409 | -0.7% | 3.11% | -10.1% |
| HOWL | Werewolf Therapeutics, Inc. | $10,507,000 | -63.1% | 2,388,011 | 0.0% | 2.82% | -45.6% | |
| BCRX | Sell | Biocryst Pharmaceuticals Inc. | $10,392,000 | +13.4% | 639,089 | -3.5% | 2.79% | +66.9% |
| TPTX | Buy | Turning Point Therapeutics, Inc. | $9,434,000 | -27.1% | 351,350 | +29.5% | 2.53% | +7.3% |
| TCRR | TCR2 Therapeutics, Inc. | $9,304,000 | -40.8% | 3,370,982 | 0.0% | 2.50% | -12.8% | |
| GERN | Buy | Geron Corporation | $8,363,000 | +21.9% | 6,149,277 | +9.3% | 2.24% | +79.4% |
| CYTK | Sell | Cytokinetics Inc. | $8,254,000 | -22.0% | 224,246 | -3.5% | 2.22% | +14.8% |
| CRNX | Sell | Crinetics Pharmaceuticals Inc. | $8,049,000 | -25.4% | 366,676 | -3.5% | 2.16% | +9.8% |
| TVTX | Sell | Travere Therapeutics Inc. | $7,163,000 | -19.8% | 277,950 | -3.5% | 1.92% | +18.0% |
| HRMY | Sell | Harmony Biosciences Hldgs Inc. | $6,690,000 | +10.1% | 137,517 | -3.5% | 1.80% | +62.1% |
| GTHX | G1 Therapeutics, Inc. | $6,512,000 | -25.6% | 856,798 | 0.0% | 1.75% | +9.6% | |
| MIRM | Sell | Mirum Pharmaceuticals Inc. | $6,353,000 | +33.3% | 288,531 | -3.5% | 1.70% | +96.2% |
| RETA | New | Reata Pharmaceuticals inc-a | $5,897,000 | – | 180,000 | +100.0% | 1.58% | – |
| YMAB | Sell | YmAbs Therapeutics, Inc. | $5,271,000 | -27.2% | 443,702 | -0.6% | 1.42% | +7.3% |
| ARQT | New | Arcutis Biotherapeutics inc | $4,979,000 | – | 258,500 | +100.0% | 1.34% | – |
| ADCT | Sell | ADC Therapeutics, Inc. | $4,912,000 | -27.9% | 334,384 | -0.9% | 1.32% | +6.1% |
| FOLD | Sell | Amicus Therapeutics Inc. | $4,693,000 | -20.8% | 495,603 | -3.5% | 1.26% | +16.5% |
| VSTM | Sell | Verastem, Inc. | $4,575,000 | -31.8% | 3,244,650 | -0.8% | 1.23% | +0.4% |
| ONCR | Oncorus, Inc. | $4,231,000 | -66.2% | 2,377,031 | 0.0% | 1.14% | -50.3% | |
| AXSM | Sell | Axsome Therapeutics Inc. | $4,132,000 | +5.8% | 99,834 | -3.5% | 1.11% | +55.8% |
| EPIX | Sell | ESSA Pharma, Inc. | $4,084,000 | -57.0% | 660,892 | -1.2% | 1.10% | -36.7% |
| EPZM | Epizyme, Inc. | $3,939,000 | -54.0% | 3,425,202 | 0.0% | 1.06% | -32.3% | |
| RLMD | New | Relmada Therapeutics inc | $3,725,000 | – | 138,000 | +100.0% | 1.00% | – |
| RVMD | Revolution Medicines, Inc. | $3,726,000 | +1.4% | 146,041 | 0.0% | 1.00% | +49.3% | |
| ACAD | Buy | Acadia Pharmaceuticals Inc | $3,675,000 | +25.9% | 151,750 | +21.4% | 0.99% | +85.3% |
| AVDL | Buy | Avadel Pharmaceuticals Plcadr | $2,816,000 | -7.2% | 412,363 | +9.9% | 0.76% | +36.7% |
| PHAT | New | Phathom Pharmaceuticals inc | $2,631,000 | – | 193,326 | +100.0% | 0.71% | – |
| KRTX | New | Karuna Therapeutics inc | $2,536,000 | – | 20,000 | +100.0% | 0.68% | – |
| NEO | Sell | Neogenomics Inc. | $1,647,000 | -65.6% | 135,573 | -3.5% | 0.44% | -49.4% |
| INZY | Sell | Inozyme Pharma Inc. | $1,206,000 | -41.6% | 294,980 | -2.5% | 0.32% | -13.8% |
| AVRO | AVROBIO, Inc. | $855,000 | -65.7% | 647,918 | 0.0% | 0.23% | -49.7% | |
| BDTX | Black Diamond Therapeutics, Inc. | $664,000 | -48.1% | 239,888 | 0.0% | 0.18% | -23.6% | |
| MEIP | Exit | MEI Pharma, Inc. | $0 | – | -12,350,971 | -100.0% | -6.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.